Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 281

1.

Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.

Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D, Lestuzzi C, Maurea N, Oliva S, Russo G, Faggiano P; Italian Cardio-Oncologic Network.

J Card Fail. 2012 Feb;18(2):113-9. doi: 10.1016/j.cardfail.2011.10.015. Epub 2011 Dec 3.

PMID:
22300778
2.

Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer.

Russo G, Cioffi G, Gori S, Tuccia F, Boccardi L, Khoury G, Lestuzzi C, Maurea N, Oliva S, Faggiano P, Tarantini L; ICARO (Italian CARdio-Oncological) Network.

J Cardiovasc Med (Hagerstown). 2014 Feb;15(2):141-6. doi: 10.2459/JCM.0b013e328365afb5.

PMID:
24534802
3.

Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J.

J Clin Oncol. 2005 Nov 1;23(31):7811-9.

PMID:
16258083
4.

High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.

Onitilo AA, Engel JM, Stankowski RV, Liang H, Berg RL, Doi SA.

Breast Cancer Res Treat. 2012 Jul;134(1):291-8. doi: 10.1007/s10549-012-2039-z. Epub 2012 Apr 4.

PMID:
22476854
5.

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP.

J Clin Oncol. 2003 Aug 1;21(15):2889-95.

PMID:
12885806
6.

Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?

Oliva S, Cioffi G, Frattini S, Simoncini EL, Faggiano P, Boccardi L, Pulignano G, Fioretti AM, Giotta F, Lestuzzi C, Maurea N, Sabatini S, Tarantini L; Italian Cardio-Oncological Network.

Oncologist. 2012;17(7):917-24. doi: 10.1634/theoncologist.2011-0445. Epub 2012 Jun 6.

7.

Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.

Şendur MA, Aksoy S, Yorgun H, Ozdemir N, Yilmaz FM, Yazıcı O, Zungun C, Aytemir K, Zengin N, Altundag K.

Curr Med Res Opin. 2015 Mar;31(3):547-56. doi: 10.1185/03007995.2015.1005834. Epub 2015 Jan 27.

PMID:
25586297
8.

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.

Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV.

BMC Cancer. 2007 Aug 8;7:153. Review.

9.

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.

Baselga J, Perez EA, Pienkowski T, Bell R.

Oncologist. 2006;11 Suppl 1:4-12. Review.

10.

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.

Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ.

J Clin Oncol. 2006 Sep 1;24(25):4107-15. Epub 2006 Aug 14. Erratum in: J Clin Oncol. 2008 May 10;26(14): 2421.

PMID:
16908934
11.

Trastuzumab-related cardiac events in the treatment of early breast cancer.

Fried G, Regev T, Moskovitz M.

Breast Cancer Res Treat. 2013 Nov;142(1):1-7. doi: 10.1007/s10549-013-2732-6. Epub 2013 Oct 24.

PMID:
24154507
12.

Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.

Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, Sarti S, Cecconetto L, Pietri E, Ferrario C, Fedeli A, Faedi M, Nanni O, Frassineti GL, Amadori D, Rocca A.

Heart. 2013 May;99(9):634-9. doi: 10.1136/heartjnl-2012-303151. Epub 2013 Jan 24.

PMID:
23349345
13.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L.

N Engl J Med. 2001 Mar 15;344(11):783-92.

14.

Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.

Stickeler E, Klar M, Watermann D, Geibel A, Földi M, Hasenburg A, Gitsch G.

Breast Cancer Res Treat. 2009 Oct;117(3):591-8. doi: 10.1007/s10549-008-0306-9. Epub 2009 Jan 21.

PMID:
19156515
15.

Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy.

Cao L, Hu WG, Kirova YM, Yang ZZ, Cai G, Yu XL, Ma JL, Guo XM, Shao ZM, Chen JY.

Cancer Radiother. 2014 Mar;18(2):119-24. doi: 10.1016/j.canrad.2014.01.001. Epub 2014 Mar 15.

PMID:
24642505
16.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team.

N Engl J Med. 2005 Oct 20;353(16):1659-72.

17.

Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.

Telli ML, Hunt SA, Carlson RW, Guardino AE.

J Clin Oncol. 2007 Aug 10;25(23):3525-33. Review.

PMID:
17687157
18.

Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab.

Chan A, McGregor SR.

Intern Med J. 2012 Mar;42(3):267-74. doi: 10.1111/j.1445-5994.2011.02432.x.

PMID:
21241440
19.

Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer.

Yu AF, Yadav NU, Lung BY, Eaton AA, Thaler HT, Hudis CA, Dang CT, Steingart RM.

Breast Cancer Res Treat. 2015 Jan;149(2):489-95. doi: 10.1007/s10549-014-3253-7. Epub 2015 Jan 1.

20.

Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.

Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, Panasci L.

J Clin Oncol. 2006 Jun 20;24(18):2773-8. Epub 2006 May 8.

PMID:
16682726

Supplemental Content

Support Center